Clinical Research Directory

Inclusion Criteria: * Men or women ≥ 18 years old. * Patients suffering from chronic pelvi-perineal neuralgia (\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC). * Patients who have signed the informed consent form for the study at the inclusion visit. * Women must meet one of the following criteria at the time of inclusion: * Use adequate contraceptive measures; * or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments); * or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels; * or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure. Exclusion Criteria: * Patients under guardianship, curatorship, or legal protection. * Pregnant or breastfeeding women. * Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components. * Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation). * Patients not affiliated with the French Social Security system. * Patients with insufficient cooperation and/or understanding to strictly comply with the protocol requirements. * Patients who have taken analgesics within the 12 hours prior to measurements.